Top entities: ADMA Biologics, Rosen Law Firm, Philip Kim, Culper Research.

What category does this event fall under?

Regulatory — classified as class action lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Rosen Law Firm announced investigation ADMA Biologics · Culper Research published report ADMA Biologics

Is this event still developing?

This is an active story, last updated Jun 11, 2026. Coverage continues to evolve.

Regulatory class action lawsuit

Rosen Law Sues ADMA Biologics

Q: When did this event occur?

First reported May 29, 2026; last updated Jun 11, 2026.

Q: What is the market impact?

Direct. The class action lawsuit against ADMA Biologics directly impacts its stock price and investor confidence, as evidenced by the 16.

Analysis based on 9 articles · First reported May 29, 2026 · Last updated Jun 11, 2026

Sentiment

-50

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit against ADMA Biologics directly impacts its stock price and investor confidence, as evidenced by the 16.6% drop following the initial allegations. The legal proceedings could result in significant financial damages for ADMA Biologics and potential recovery for affected investors. This event highlights the risks associated with alleged corporate misconduct and the role of investor rights law firms like Rosen Law Firm in seeking accountability.

Biotechnology Legal Services

Event Summary

Rosen Law Firm has filed a class action lawsuit against ADMA Biologics on behalf of investors who purchased its securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics made false and misleading statements by engaging in an undisclosed related party transaction, using channel stuffing to inflate revenue, and lacking adequate internal controls. These allegations surfaced after Culper Research released a report, which was then covered by Investing.com, causing ADMA Biologics' stock to fall by 16.6% on March 24, 2026. Rosen Law Firm is encouraging affected investors to join the class action and potentially serve as lead plaintiff.

Key Actions

100 Rosen Law Firm announced investigation ADMA Biologics

80 Culper Research published report ADMA Biologics

Entities Involved

stock

ADMA Biologics

ADMA Biologics is the target of a class action lawsuit alleging misleading business practices, including undisclosed related party transactions, channel stuffing, and inadequate internal controls. Its stock price fell 16.6% on March 24, 2026, following short seller allegations.

Importance 100 Sentiment -70

priv

Rosen Law Firm

Rosen Law Firm filed a class action lawsuit against ADMA Biologics on behalf of investors, seeking to recover damages under federal securities laws. The firm is actively encouraging investors to join the lawsuit and potentially serve as lead plaintiff.

Importance 90 Sentiment 50

per

Philip Kim

Philip Kim, an attorney at Rosen Law Firm, is the primary contact for investors interested in joining the class action lawsuit against ADMA Biologics.

Importance 40 Sentiment 0

priv

Culper Research

Culper Research released a report alleging that ADMA Biologics engaged in channel stuffing to inflate revenue growth, which triggered the initial stock price decline and subsequent class action lawsuit.

Importance 30 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard